Approval & regulatory record · Bremelanotide · NDA 210557
PT-141 is an approved drug for one narrow use — and a research-grade peptide for everything else.
A measured clinical reading of the bremelanotide record: the one indication the FDA cleared, the studies behind it, and the line between label-attested fact and study-attested finding.
The short version
PT-141 is the lab name for bremelanotide, a small synthetic peptide that acts on the brain rather than the blood vessels. It switches on a set of brain receptors (called melanocortin receptors, the same family the body's own "alpha-MSH" hormone uses) that help drive sexual desire. That central-brain route is what makes it different from the more familiar erection pills, which work on blood flow in the body.
Here is the one fact that organizes everything else: in 2019 the FDA approved bremelanotide for a single, narrow use — low sexual desire that causes distress (called HSDD) in women who have not yet reached menopause [7]. That approval does not cover men, postmenopausal women, or "performance." Those uses have been studied to varying degrees but are off-label or research-grade, and we label them that way throughout this site.
What to watch for is real: nausea is common, blood pressure can rise briefly, and repeated dosing can darken the skin [3][4][7]. The honest benefits, the reported effects, and the downsides are laid out on PT-141 effects.
What is PT-141
PT-141 is a synthetic cyclic heptapeptide — a ring of seven amino acids — that acts as an agonist (a switch that turns a receptor on) at melanocortin receptors, chiefly MC4R and MC3R [1]. These receptors sit mostly in the central nervous system, in hypothalamic circuits tied to sexual motivation. Its international nonproprietary name is bremelanotide; the two names refer to the same molecule [7].
Mechanistically it is a relative of the tanning peptide melanotan-II, re-engineered so the C-terminal end carries a carboxylic acid instead of an amide [12]. That small change shifts the molecule toward the sexual-desire pathway. When given systemically, it produced penile erections in rats and nonhuman primates and activated hypothalamic neurons (measured as increased c-Fos), and it produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early trials [1]. The central, brain-first mechanism is the throughline of the whole literature.
What is PT-141 peptide, in one paragraph
The PT-141 peptide is bremelanotide: sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight about 1025 Da, CAS 189691-06-3 [7]. The "cyclo" part means a lactam bridge closes the ring between two side chains, which makes it more stable than a straight-chain peptide. It is not made by the body; it is a synthetic analogue of alpha-MSH, a natural melanocortin hormone cleaved from a precursor protein called POMC [1]. As a pharmaceutical it is dosed by subcutaneous injection; the early intranasal form was dropped during development for inconsistent absorption [10].
Why this site leads with approval status
Most of what circulates about PT-141 blurs a line that actually matters: the difference between an approved drug and a research-grade peptide sold under the same lab name. Bremelanotide cleared two pivotal Phase 3 trials (the RECONNECT program, 1,267 premenopausal women with HSDD) and a 52-week open-label extension before approval [3][4]. That is real human evidence — for that one population, at one dose, by one route.
The "PT-141" sold as a research chemical sits outside that framework entirely: no regulatory oversight of identity, purity, or concentration. This site reads the published record straight and keeps approved use, off-label use, and research-grade material clearly separated. Start with is PT-141 fda-approved, or read the evidence summary at PT-141 reviews.
How the record is organized here
The mechanism and the key trials are summarized on PT-141 research. The label-attested approved dose and the studied dose ranges — research context only, no recommendation — are on the dosage page. The benefits, the reported effects, and the cited safety cautions are on PT-141 effects. Every quantitative claim on the site maps to a numbered source on PT-141 references. Nothing here is medical advice, and no dose is recommended for any individual.